마이크로플루이딕스 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 제품별, 재료별, 용도별, 지역별, 부문별 예측(2025-2030년)

Microfluidics Market Growth & Trends:

The global microfluidics market size is expected to reach USD 73.85 billion by 2030, registering CAGR of 11.99% from 2025 to 2030, according to a new report by Grand View Research, Inc. The demand for microfluidics-based devices is expected to increase due to the introduction of improved technology such as digital microfluidics, which enables on-chip biochemical analysis. An increase in research activities undertaken by analytical and clinical researchers have also driven the demand for microfluidics device. For instance, in May 2022, a research team from the University of Minnesota developed an innovative microfluidic chip for disease diagnosing that uses a minimum number of components and can be operated wirelessly by a smartphone.

Miniature microfluidic-based tools are gaining significant popularity among consumers, which has encouraged companies to invest in their development. Since microfluidics is the underlying principle of lab-on-a-chip devices, it offers various benefits such as minimal sample volume, minimal reagent usage, reduced waste, and rapid processing. Fully automated microfluidics with enhanced functional capabilities, and robust modularity are creating growth opportunities for manufacturers operating in the market. This can be attributed to the fact that modular chips can interface with several instruments. In addition, companies operating in the field of drug discovery are striving to minimize overhead costs and timelines to offset the estimated decline in revenue owing to a significant number of drugs going off-patent.

The implementation of microfluidics is expanding in the field of diagnostics, especially in POC diagnostics. This is also supplemented by microfluidics-integrated biosensor technologies that are expected to enhance POC diagnostics. The combination of microfluidic components with POC devices is largely focused on achieving sensitivity, stability, accuracy, affordability, and obtaining minimally invasive POC technology. Microfluidic POC technologies are expected to enhance patient care by ensuring personalization, early disease detection, and easy monitoring.

In addition, COVID-19 has further upscaled the use of microfluidics. Point-of-care testing involves small equipment, regulates the process, and has limited testing cycles. This allows single or multiple research laboratory services to evaluate biological samples and diagnose harmful diseases simultaneously. In general, stage assessment and rapid detection of viral epidemics are vital to overcoming pandemic situations and diagnosing rapidly. Therefore, combining microfluidic devices with point-of-care testing enhances detection efficiency. At the same time, point-of-care testing of microfluidic chips enhances user accessibility, improves sensitivity and accuracy, and reduces the detection time, all of which are advantageous in detecting SARS-CoV-2.

Further, several acquisitions in the microfluidics industry are aimed at enhancing technologies for expanding the scope of microfluidics-related applications. In June 2021, Danaher Corporation announced that Precision NanoSystems (PNI), a Canada-based solution provider, was acquired by its life science business. PNI offered proprietary genetic toolkit platforms, including LNP delivery and nanoparticle manufacturing via the microfluidic-based platform, which further complemented the company's portfolio of life science products.

On the other hand, high operational costs hinder the microfluidics market growth to a certain extent. The fabrication of microfluidics chips has certain issues such as open channel construction that require bonding of machine parts to form a final enclosed structure. The open channel is formed by the etching of glass or silicon. This step is slow, costly, and requires the use of aggressive chemicals. In addition, most of the microfluidic prototyping methods are not compatible with the batch process, and are also complicated and costly.

Microfluidics Market Report Highlights:

• Based on application, the medical segment held the largest revenue share in 2024. Microfluidics is a significant technology in biological analysis, chemical synthesis, and information technology.
• Based on material, the polydimethylsiloxane (PDMS) segment held the highest revenue share of 36.60% in 2024. PDMS is a widely used polymer in microfluidics owing to the several advantages offered by the material.
• Based on technology, Lab-on-a-chip segment held the highest market share of 37.49% in 2024. Lab-on-a-chip research has recently shown potential in cell biology.
• North America microfluidics market dominated the global market with a revenue share of 42.3% in 2024. This dominance is primarily driven by strong research funding from both government bodies and private industries

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Application Segment
  • 1.2.3. Material Segment
  • 1.2.4. Technology Segment
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Advancements in 3D Printing & Digital Manufacturing
    • 3.2.1.2. Rising Research & Development Investments
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High initial costs
• 3.3. Microfluidics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Microfluidics Market: Product Business Analysis

• 4.1. Product Segment Dashboard
• 4.2. Global Microfluidics Market Product Movement Analysis
• 4.3. Global Microfluidics Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Microfluidic-based Devices
  • 4.4.1. Global Microfluidic based Devices Market, 2018 - 2030 (USD Million)
  • 4.4.2. Chips
    • 4.4.2.1. Global Chips Market, 2018 - 2030 (USD Million)
  • 4.4.3. Micro-pumps
    • 4.4.3.1. Global Micro-pumps Market, 2018 - 2030 (USD Million)
  • 4.4.4. Sensors
    • 4.4.4.1. Global Sensors Market, 2018 - 2030 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Global Others Market, 2018 - 2030 (USD Million)
• 4.5. Microfluidic Components
  • 4.5.1. Global Microfluidic Components Market, 2018 - 2030 (USD Million)

Chapter 5. Microfluidics Market: Application Business Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global Microfluidics Market Application Movement Analysis
• 5.3. Global Microfluidics Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Medical
  • 5.4.1. Pharmaceuticals
    • 5.4.1.1. Global Pharmaceuticals Market, 2018 - 2030 (USD Million)
  • 5.4.2. Medical Devices
    • 5.4.2.1. Global Medical Devices Market, 2018 - 2030 (USD Million)
  • 5.4.3. In-vitro Diagnostics
    • 5.4.3.1. Global In-vitro Diagnostics Market, 2018 - 2030 (USD Million)
  • 5.4.4. Others
    • 5.4.4.1. Global Others Market, 2018 - 2030 (USD Million)
• 5.5. Non-Medical
  • 5.5.1. Global Non-Medical Market, 2018 - 2030 (USD Million)

Chapter 6. Microfluidics Market: Material Business Analysis

• 6.1. Material Segment Dashboard
• 6.2. Global Microfluidics Market Material Movement Analysis
• 6.3. Global Microfluidics Market Size & Trend Analysis, by Material, 2018 to 2030 (USD Million)
• 6.4. Silicon
  • 6.4.1. Global Silicon Market, 2018 - 2030 (USD Million)
• 6.5. Glass
  • 6.5.1. Global Glass Market, 2018 - 2030 (USD Million)
• 6.6. Polymer
  • 6.6.1. Global Polymer Market, 2018 - 2030 (USD Million)
• 6.7. Polydimethylsiloxane (PDMS)
  • 6.7.1. Global Polydimethylsiloxane (PDMS) Market, 2018 - 2030 (USD Million)
• 6.8. Others
  • 6.8.1. Global Others Market, 2018 - 2030 (USD Million)

Chapter 7. Microfluidics Market: Technology Business Analysis

• 7.1. Technology Segment Dashboard
• 7.2. Global Microfluidics Market Technology Movement Analysis
• 7.3. Global Microfluidics Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 7.4. Lab-on-a-chip
  • 7.4.1. Global Lab-on-a-chip Market, 2018 - 2030 (USD Million)
• 7.5. Organs-on-chips
  • 7.5.1. Global Organs-on-chips Market, 2018 - 2030 (USD Million)
• 7.6. Continuous flow microfluidics
  • 7.6.1. Global Continuous Flow Microfluidics Market, 2018 - 2030 (USD Million)
• 7.7. Optofluidics and microfluidics
  • 7.7.1. Global Optofluidics and microfluidics Market, 2018 - 2030 (USD Million)
• 7.8. Acoustofluidics and microfluidics
  • 7.8.1. Global Acoustofluidics and microfluidics Market, 2018 - 2030 (USD Million)
• 7.9. Electrophoresis and microfluidics
  • 7.9.1. Global Electrophoresis and microfluidics Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Microfluidics Market: Region Estimates & Trend Analysis

• 8.1. North America
  • 8.1.1. North America market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.1.2. U.S.
    • 8.1.2.1. Key country dynamics
    • 8.1.2.2. Competitive scenario
    • 8.1.2.3. Regulatory Framework
    • 8.1.2.4. Target Disease Prevalence
    • 8.1.2.5. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.1.3. Canada
    • 8.1.3.1. Key country dynamics
    • 8.1.3.2. Competitive scenario
    • 8.1.3.3. Regulatory Framework
    • 8.1.3.4. Target Disease Prevalence
    • 8.1.3.5. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.1.4. Mexico
    • 8.1.4.1. Key country dynamics
    • 8.1.4.2. Competitive scenario
    • 8.1.4.3. Regulatory Framework
    • 8.1.4.4. Target Disease Prevalence
    • 8.1.4.5. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 8.2. Europe
  • 8.2.1. Europe market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.2.2. UK
    • 8.2.2.1. Key country dynamics
    • 8.2.2.2. Competitive scenario
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Target Disease Prevalence
    • 8.2.2.5. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.2.3. Germany
    • 8.2.3.1. Key country dynamics
    • 8.2.3.2. Competitive scenario
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Target Disease Prevalence
    • 8.2.3.5. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.2.4. France
    • 8.2.4.1. Key country dynamics
    • 8.2.4.2. Competitive scenario
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Target Disease Prevalence
    • 8.2.4.5. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.2.5. Italy
    • 8.2.5.1. Key country dynamics
    • 8.2.5.2. Competitive scenario
    • 8.2.5.3. Regulatory Framework
    • 8.2.5.4. Target Disease Prevalence
    • 8.2.5.5. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.2.6. Spain
    • 8.2.6.1. Key country dynamics
    • 8.2.6.2. Competitive scenario
    • 8.2.6.3. Regulatory Framework
    • 8.2.6.4. Target Disease Prevalence
    • 8.2.6.5. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.2.7. Norway
    • 8.2.7.1. Key country dynamics
    • 8.2.7.2. Competitive scenario
    • 8.2.7.3. Regulatory Framework
    • 8.2.7.4. Target Disease Prevalence
    • 8.2.7.5. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.2.8. Sweden
    • 8.2.8.1. Key country dynamics
    • 8.2.8.2. Competitive scenario
    • 8.2.8.3. Regulatory Framework
    • 8.2.8.4. Target Disease Prevalence
    • 8.2.8.5. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.2.9. Denmark
    • 8.2.9.1. Key country dynamics
    • 8.2.9.2. Competitive scenario
    • 8.2.9.3. Regulatory Framework
    • 8.2.9.4. Target Disease Prevalence
    • 8.2.9.5. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 8.3. Asia Pacific
  • 8.3.1. Asia Pacific market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.3.2. Japan
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Competitive scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Target Disease Prevalence
    • 8.3.2.5. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.3.3. China
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Competitive scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Target Disease Prevalence
    • 8.3.3.5. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.3.4. India
    • 8.3.4.1. Key country dynamics
    • 8.3.4.2. Competitive scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Target Disease Prevalence
    • 8.3.4.5. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.3.5. Thailand
    • 8.3.5.1. Key country dynamics
    • 8.3.5.2. Competitive scenario
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Target Disease Prevalence
    • 8.3.5.5. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.3.6. South Korea
    • 8.3.6.1. Key country dynamics
    • 8.3.6.2. Competitive scenario
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Target Disease Prevalence
    • 8.3.6.5. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.3.7. Australia
    • 8.3.7.1. Key country dynamics
    • 8.3.7.2. Competitive scenario
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Target Disease Prevalence
    • 8.3.7.5. Australia market estimates and forecasts 2018 - 2030 (USD Million)
• 8.4. Latin America
  • 8.4.1. Latin America market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.4.2. Brazil
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Competitive scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Target Disease Prevalence
    • 8.4.2.5. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.4.3. Argentina
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Competitive scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Target Disease Prevalence
    • 8.4.3.5. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 8.5. Middle East & Africa
  • 8.5.1. Middle East & Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.5.2. South Africa
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Competitive scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Target Disease Prevalence
    • 8.5.2.5. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.5.3. Saudi Arabia
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Competitive scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Target Disease Prevalence
    • 8.5.3.5. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.5.4. UAE
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Competitive scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Target Disease Prevalence
    • 8.5.4.5. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.5.5. Kuwait
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Competitive scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Target Disease Prevalence
    • 8.5.5.5. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. Illumina, Inc.
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. F. Hoffmann-La Roche Ltd.
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Revitty
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Agilent Technologies, Inc.
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Danaher
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Bio-Rad Laboratories, Inc.
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. thinXXS Microtechnology GmbH
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Abbott
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Thermo Fisher Scientific, Inc.
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Standard BioTools
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives